Diagnosis and Management of Alcoholic Hepatitis

Clinics in Liver Disease

Volumn 16, Issue 4, 2012, Pages 717-736

  Sohail, Umair ^a   Satapathy, Sanjaya K ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b METHODIST UNIVERSITY HOSPITAL   (United States)

Author keywords

Alcoholic hepatitis; Aminotransferases; Enteral nutrition in alcoholic hepatitis; Liver biopsy; Liver transplantation; Maddrey's discriminant function; Pentoxifylline; Steroids in alcoholic hepatitis

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BACLOFEN; BILIRUBIN; CARBOHYDRATE DEFICIENT TRANSFERRIN; COLCHICINE; CORTICOSTEROID; CREATININE; DISULFIRAM; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON; GLUCOCORTICOID; INFLIXIMAB; INSULIN; MALOTILATE; METADOXINE; METHYLPREDNISOLONE; OXANDROLONE; PARACETAMOL; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; POLYUNSATURATED LECITHIN; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; UNCLASSIFIED DRUG;

AGE; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLISM; CHILD TURCOTTE PUGH SCORE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL HEMORRHAGE; GLASGOW ALCOHOLIC HEPATITIS SCORE; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LEUKAPHERESIS; LEUKOCYTOPHARESIS; LILLE MODEL; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER REGENERATION; LIVER TRANSPLANTATION; MADDREY DISCRIMINANT FUNCTION INDEX; MALNUTRITION; MAYO END STAGE LIVER DISEASE SCORE; MORTALITY; NONHUMAN; PROTEIN DEGRADATION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTIOXIDANTS; BIOPSY; HEPATITIS, ALCOHOLIC; HUMANS; LIVER; LIVER REGENERATION; LIVER TRANSPLANTATION; NUTRITION THERAPY; PENTOXIFYLLINE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TEMPERANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867948755     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.08.005     Document Type: Review

References (112)

1. Savolainen V.T., Liesto K., Männikkö A., et al. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res 1993, 17:1112-1117.
2. Lelbach W.K. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci 1975, 252:85-105.
3. Grant B.F., Dufour M.C., Harford T.C. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988, 8:12-25.
4. Lu X.L., Luo J.Y., Tao M., et al. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004, 10:2423-2426.
5. Maddrey W.C. Alcoholic hepatitis: clinicopathologic features and therapy. Semin Liver Dis 1998, 8:91-102.
6. Levitsky J., Mailliard M.E. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004, 24:233-247.
7. Uchida T., Kao H., Quispe-Sjogren M., et al. Alcoholic foamy degeneration-a pattern of acute alcoholic injury of the liver. Gastroenterology 1983, 84:683-692.
8. Nanji A.A., French S.W., Mendenhall C.L. Serum aspartate aminotransferase to alanine aminotransferase ratio in human and experimental alcoholic liver disease: relationship to histologic changes. Enzyme 1989, 41:112-115.
9. Cohen J.A., Kaplan M.M. The SGOT/SGPT ratio-an indicator of alcoholic liver disease. Dig Dis Sci 1979, 24:835-838.
10. Niemela O. Biomarkers in alcoholism. Clin Chim Acta 2007, 377:39-49.
11. Nyblom H., Berggren U., Balldin J., et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol 2004, 39:336-339.
12. Yersin B., Nicolet J.F., Dercrey H., et al. Screening for excessive alcohol drinking. Comparative value of carbohydrate- deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med 1995, 155:1907-1911.
13. Conigrave K.M., Degenhardt L.J., Whitfield J.B., et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002, 26:332-339.
14. Sillanaukee P., Massot N., Jousilahti P., et al. Dose response of laboratory markers to alcohol consumption in a general population. Am J Epidemiol 2000, 152:747-751.
15. Alte D., Luedemann J., Rose H.J., et al. Laboratory markers carbohydrate- deficient transferrin, gamma-glutamyl transferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004, 28:931-940.
16. Reynaud M., Schellenberg F., Loisequx-Meunier M.N., et al. Objective diagnosis of alcohol abuse: compared values of carbohydrate-deficient transferrin (CDT), gamma-glutamyl transferase (GGT), and mean corpuscular volume (MCV). Alcohol Clin Exp Res 2000, 24:1414-1419.
17. Poynard T., Zourabichvili O., Hilpert G., et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984, 4:324-327.
18. Naveau S., Poynard T., Abella A., et al. Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients. Hepatology 1985, 5:819-823.
19. Bortolotti F., De Paoli G., Tagliaro F. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 841:96-109.
20. De Feo T.M., Fargion S., Duca L., et al. Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. Hepatology 1999, 29:658-663.
21. Schmitt U.M., Stieber P., Jüngst D., et al. Carbohydrate-deficient transferrin is not a useful marker for the detection of chronic alcohol abuse. Eur J Clin Invest 1998, 28:615-621.
22. Wurst F.M., Alling C., Aradottir S., et al. Emerging biomarkers: new directions and clinical applications. Alcohol Clin Exp Res 2005, 29:465-473.
23. Zimmer H., Schmitt G., Aderjan R. Preliminary immunochemical test for the determination of ethyl glucuronide in serum and urine: comparison of screening method results with gas chromatography-mass spectrometry. J Anal Toxicol 2002, 26:11-16.
24. Katoonizadeh A., Laleman W., Verslype C., et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010, 59:1561-1569.
25. Mookerjee R.P., Lackner C., Stauber R., et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011, 55:1103-1111.
26. Tannapfel A., Denk H., Dienes H.P., et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011, 458:511-523.
27. Chedid A., Mendenhall C.L., Tosch T., et al. Significance of megamitochondria in alcoholic liver disease. Gastroenterology 1986, 90:1858-1864.
28. Maddrey W.C., Boitnott J.K., Bedine M.S., et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
29. Carithers R.L., Herlong H.F., Diehl A.M., et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989, 110:685-690.
30. Mathurin P., Mendenhall C.L., Carithers R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002, 36:480-487.
31. McCullough A.J., O'Connor J.F. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2022-2036.
32. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
33. Sheth M., Riggs M., Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002, 2:2.
34. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41:353.
35. Srikureja W., Kyulo N.L., Runyon B.A., et al. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005, 42:700.
36. Kamath P.S., Kim W.R. Is the change in MELD score a better indicator of mortality than baseline MELD score?. Liver Transpl 2003, 9:19-21.
37. O'Shea R.S., Dasarathy S., McCullough A.J. Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010, 51:307-328.
38. Forrest E.H., Evans C.D., Stewart S., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54:1174-1179.
39. Forrest E.H., Morris A.J., Stewart S., et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007, 56:1743.
40. Friedman L.S. The risk of surgery in patients with liver disease. Hepatology 1999, 29:1617-1623.
41. Jeong J.Y., Sohn J.H., Son B.K., et al. Korean J Gastroenterol 2007, 49:93-99. [in Korean].
42. Garrison R.N., Cryer H.M., Howard D.A., et al. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984, 199:648-655.
43. Dominguez M., Rincón D., Abraldes J.G., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008, 103:2747-2756.
44. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45:1348-1354.
45. Pessione F., Ramond M.J., Peters L., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003, 23:45-53.
46. Borowsky S.A., Strome S., Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981, 80:1405-1409.
47. Brunt P.W., Kew M.C., Scheuer P.J., et al. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut 1974, 15:52-58.
48. Luca A., Garcia-Pagan J.C., Bosch J., et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997, 112:1284-1289.
49. Pares A., Caballeria J., Bruguera M., et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986, 2:33-42.
50. Powell W.J., Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968, 44:406-420.
51. Garbutt J.C., West S.L., Carey T.S., et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281:1318-1325.
52. Alcoholic Liver Disease: Robert S, O'Shea, et al. The Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology.
53. Rösner S., Hackl-Herrwerth A., Leucht S., et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, (9). CD004332.
54. Leggio L., Ferrulli A., Zambon A., et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. J Addict Behav 2012, 37:561-564.
55. DiCecco S.R., Francisco-Ziller N. Nutrition in alcoholic liver disease. Nutr Clin Pract 2006, 21:245-254.
56. Mendenhall C.L., Anderson S., Weesner R.E., et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984, 76:211.
57. Cabre E., Gonzalez-Huix F., Abad-Lacruz A., et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990, 98:715.
58. Kearns P.J., Young H., Garcia G., et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992, 102:200.
59. Koretz R.L., Avenell A., Lipman T.O. Nutritional support for liver disease. Cochrane Database Syst Rev 2012, (5). CD008344.
60. Swart G.R., Zillikens M.C., van Vuure J.K., et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ 1989, 299:1202.
61. Tan H.H., Virmani S., Martin P. Controversies in the management of alcoholic liver disease. Mt Sinai J Med 2009, 76(5):484-498.
62. Shumaker J.B., Resnick R.H., Galambos J.T., et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978, 69:443-449.
63. Ramond M.J., Poynard T., Rueff B., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512.
64. Helman R.A., Temko M.H., Nye S.W., et al. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971, 74:311-321.
65. Porter H.P., Simon F.R., Pope C.E., et al. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971, 284:1350-1355.
66. Campra J.L., Hamlin E.M., Kirshbaum R.J., et al. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973, 79:625-631.
67. Blitzer B.L., Mutchnick M.G., Joshi P.H., et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977, 22:477-484.
68. Depew W., Boyer T., Omata M., et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980, 78:524-529.
69. Theodossi A., Eddleston A.L., Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982, 23:75-79.
70. Lesesne H.R., Bozymski E.M., Fallon H.J. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978, 74:169-173.
71. Mendenhall C.L., Anderson S., Garcia-Pont P., et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984, 311:1464-1470.
72. Imperiale T.F., McCullough A.J. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990, 113:299-307.
73. Christensen E., Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995, 37:113-118.
74. Mathurin P., O'Grady J., Carithers R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011, 60:255-260.
75. Rambaldi A., Saconato H.H., Christensen E., et al. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008, 27:1167-1178.
76. Morris J.M., Forrest E.H. Bilirubin response to corticosteroids in severe alcoholic hepatitis. Eur J Gastroenterol Hepatol 2005, 17:759-762.
77. Mathurin P., Abdelnour M., Ramond M.J., et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003, 38:1363-1369.
78. Cabré E., Rodríguez-Iglesias P., Caballería J., et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
79. Sidhu S.S., Goyal O., Singla P., et al. Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial). Dig Dis Sci 2012, 57:1664-1671.
80. Nguyen-Khac E., Thevenot T., Piquet M.A., et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011, 365:1781-1789.
81. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
82. McHutchison J.G., Runyon B.A., Draguesku J.O., et al. Pentoxifylline may prevent renal impairment in severe alcoholic hepatitis. Hepatology 1991, 14:96A.
83. Lebrec D., Dominique T., Oberti F., et al. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized placebo controlled double blind trial. Hepatology 2007, 46:A249-A250.
84. Sidhu S., Singla M., Bhatia K.L. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology 2006, 44(Suppl 1):373A-374A.
85. Paladugu H., Sawant P., Dalvi L., et al. Role of pentoxifylline in treatment of severe acute alcoholic hepatitis - a randomized controlled trial. J Gastroenterol Hepatol 2006, 21:A459.
86. De B.K., Gangopadhyay S., Dutta D., et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15:1613-1619.
87. Whitfield K., Rambaldi A., Wetterslev J., et al. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009, (4). CD007339.
88. Louvet A., Diaz E., Dharancy S., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008, 48:465-470.
89. Spahr L., Rubbia-Brandt L., Frossard J.L., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37:448-455.
90. Boetticher N.C., Peine C.J., Kwo P., et al. A randomized, double-blinded, placebo-controlled multicenter trial of Etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008, 135:1953-1960.
91. Caballería J., Parés A., Brú C., et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 1998, 28:54-60.
92. Orrego H., Kalant H., Israel Y., et al. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979, 76:105-115.
93. Hallé P., Paré P., Kaptein E., et al. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982, 82:925-931.
94. Israel Y., Walfish P.G., Orrego H., et al. Thyroid hormones in alcoholic liver disease. Effect of treatment with 6-n-propylthiouracil. Gastroenterology 1979, 76:116-122.
95. Kershenobich D., Vargas F., Garcia-Tsao G., et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988, 318:1709-1713.
96. Rambaldi A., Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005, (2). CD002148.
97. Li J., Kim C.I., Leo M.A., et al. Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 1992, 15:373-381.
98. Lieber C.S., Robins S.J., Li J., et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994, 106:152-159.
99. Rambaldi A., Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2006, (4). CD003045.
100. Trinchet J.C., Balkau B., Poupon R.E., et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992, 15:76-81.
101. Bird G., Lau J.Y., Koskinas J., et al. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991, 14:1097-1101.
102. Keiding S., Badsberg J.H., Becker U., et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival. J Hepatol 1994, 20:454-460.
103. Parés A., Deulofeu R., Cisneros L., et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care 2009, 13:R8.
104. Laleman W., Wilmer A., Evenepoel P., et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006, 10:R108.
105. Jalan R., Sen S., Steiner C., et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003, 38:24-31.
106. Wolff B., Machill K., Schumacher D., et al. MARS dialysis in decompensated alcoholic liver disease: a single-center experience. Liver Transpl 2007, 13:1189-1192.
107. Tsuji Y., Kumashiro R., Ishii K., et al. Severe alcoholic hepatitis successfully treated by leukocytapheresis: a case report. Alcohol Clin Exp Res 2003, 27:26S-31S.
108. Okubo K., Yoshizawa K., Okiyama W., et al. Severe alcoholic hepatitis with extremely high neutrophil count successfully treated by granulocytapheresis. Intern Med 2006, 45:155-158.
109. Dureja P., Lucey M.R. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol 2010, 52:759-764.
110. McCallum S., Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006, 41:358-363.
111. Castel H., Moreno C., Antonini T., et al. Early transplantation improves survival of non-responders to steroids in severe alcoholic hepatitis: a challenge to the 6 month rule of abstinence. Hepatology 2009, 50(Suppl 4):307A.
112. Mathurin P., Moreno C., Samuel D., et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011, 365:1790-1800.